FY2027 Earnings Forecast for Annexon Issued By HC Wainwright

Annexon, Inc. (NASDAQ:ANNX) – Investment analysts at HC Wainwright dropped their FY2027 earnings per share (EPS) estimates for shares of Annexon in a research note issued to investors on Friday, November 15th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of $0.49 for the year, down from their prior estimate of $0.58. HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Annexon’s FY2028 earnings at $0.90 EPS.

A number of other brokerages also recently issued reports on ANNX. Needham & Company LLC reissued a “buy” rating and set a $16.00 price objective on shares of Annexon in a research report on Friday. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research report on Friday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Annexon Trading Down 3.3 %

Shares of NASDAQ:ANNX opened at $6.12 on Monday. The business has a 50-day moving average price of $6.91 and a 200 day moving average price of $5.92. The company has a market capitalization of $646.58 million, a price-to-earnings ratio of -5.83 and a beta of 1.23. Annexon has a 12-month low of $2.27 and a 12-month high of $8.40.

Insider Buying and Selling at Annexon

In other Annexon news, EVP Ted Yednock sold 5,408 shares of Annexon stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $7.41, for a total value of $40,073.28. Following the completion of the transaction, the executive vice president now directly owns 71,365 shares of the company’s stock, valued at $528,814.65. The trade was a 7.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 20,908 shares of company stock valued at $135,768 in the last three months. 12.67% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Annexon

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in shares of Annexon by 18.3% in the 3rd quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock valued at $12,693,000 after buying an additional 331,269 shares during the period. Barclays PLC boosted its stake in shares of Annexon by 212.0% in the 3rd quarter. Barclays PLC now owns 177,765 shares of the company’s stock valued at $1,052,000 after buying an additional 120,789 shares during the period. Wellington Management Group LLP boosted its stake in shares of Annexon by 36.2% in the 3rd quarter. Wellington Management Group LLP now owns 263,360 shares of the company’s stock valued at $1,559,000 after buying an additional 69,941 shares during the period. State Street Corp boosted its stake in shares of Annexon by 116.6% in the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock valued at $22,744,000 after buying an additional 2,068,294 shares during the period. Finally, Quarry LP purchased a new position in shares of Annexon in the 3rd quarter valued at about $118,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.